Piramal Enterprises has received approval from US Food and Drug Administration (USFDA) for its investigational new drug (IND), P11187, which aims to target diabetes. This will enable the company to initiate a Phase I clinical trial of new chemical entity (NCE) in healthy volunteers in the US.
It is a potential therapeutic target for Type 2 Diabetes Mellitus (T2DM). T2DM is an emerging worldwide health crisis with an incidence rate of 300 million by 2025 as predicted by the WHO and accounts for about 90 per cent of the diabetic population.
Piramal Healthcare, formerly known as Nicholas Piramal, is one of the largest pharmaceutical companies in India. Being part of Piramal Group, its healthcare division contributes 50% to group’s revenue.
